SCHEMBL2906700

SCHEMBL2906700

Cc1ccc(CNc2ccc3c(/C=C/c4cccc(S(N)(=O)=O)c4)cccc3n2)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
PDE5A O76074 2/20 0.34
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 2/20 0.33
NPY5R Q15761 1/20 0.33
CLK1 P49759 2/20 0.33
CLK2 P49760 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906701 1.00 NPC1 (0.37) NPC1RAB9ABRD4CREBBPPDE5A
SCHEMBL2908188 0.86 RAB9A (0.45) NPC1RAB9APDE5ALMNAHTT
SCHEMBL2908184 0.86 RAB9A (0.45) NPC1RAB9APDE5ALMNAHTT
SCHEMBL2907472 0.81 NPC1 (0.36) NPC1RAB9APDE5ALMNAHTT
SCHEMBL2907471 0.81 NPC1 (0.36) NPC1RAB9APDE5ALMNAHTT
SCHEMBL2905168 0.80 NPC1 (0.39) NPC1RAB9ALMNAHTTSMN1; SMN2
SCHEMBL2905170 0.80 NPC1 (0.39) NPC1RAB9ALMNAHTTSMN1; SMN2
SCHEMBL2904762 0.80 NPC1 (0.43) NPC1RAB9APDE5ASMN1; SMN2KDM4E
SCHEMBL2906854 0.80 NPC1 (0.41) NPC1RAB9APDE5ALMNAHTT
SCHEMBL2249132 0.78 NPC1 (0.44) NPC1RAB9ALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 NPC1 1573/4885RAB9A 1336/4885BRD4 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.